Current Status of Vandetanib (ZD6474) in the Treatment of Non-small Cell Lung Cancer

Overview

Journal Biologics

Date 2010 Sep 23

PMID 20859451

Citations 5

Authors

Jaclyn Flanigan

Hari Deshpande

Scott Gettinger

Affiliations

Soon will be listed here.

Abstract

Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged as instrumental in the growth and metastasis of multiple malignancies, including non-small cell lung cancer (NSCLC). Indeed, inhibitors of each pathway have been approved by the US Food and Drug Administration for use in advanced NSCLC. As there is considerable cross talk between these pathways, dual inhibition with such agents has become an attractive strategy, with encouraging Phase II clinical trial data to date. The convenience of one oral agent targeting both pathways is clear, and clinical trials have established the maximum tolerated daily dose of vandetanib, with data from randomized Phase III trials emerging. This report will review completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the future of this agent in NSCLC.

Citing Articles

Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.

Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K Genome Biol. 2015; 16:66.

PMID: 25887790 PMC: 4450998. DOI: 10.1186/s13059-015-0636-y.

[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].

Guo L, Tang J, Meng Q, Zhu Y, Xu L, Shi H Zhongguo Fei Ai Za Zhi. 2012; 15(2):122-6.

PMID: 22336242 PMC: 6000258. DOI: 10.3779/j.issn.1009-3419.2012.02.11.

RET, ROS1 and ALK fusions in lung cancer.

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S Nat Med. 2012; 18(3):378-81.

PMID: 22327623 DOI: 10.1038/nm.2658.

Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Siegfried J, Gubish C, Rothstein M, Henry C, Stabile L J Thorac Oncol. 2012; 7(3):485-95.

PMID: 22258476 PMC: 3288546. DOI: 10.1097/JTO.0b013e31824177ea.

Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival.

Giatromanolaki A, Sivridis E, Bechrakis N, Willerding G, St Charitoudis G, Foerster M Clin Exp Metastasis. 2011; 29(1):11-7.

PMID: 21984395 DOI: 10.1007/s10585-011-9424-6.

References

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

Tonra J, Deevi D, Corcoran E, Li H, Wang S, Carrick F . Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006; 12(7 Pt 1):2197-207. DOI: 10.1158/1078-0432.CCR-05-1682. View

Davies A, Ho C, Lara Jr P, Mack P, Gumerlock P, Gandara D . Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006; 7(6):385-8. DOI: 10.3816/CLC.2006.n.021. View

Herbst R, ONeill V, Fehrenbacher L, Belani C, Bonomi P, Hart L . Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007; 25(30):4743-50. DOI: 10.1200/JCO.2007.12.3026. View

Holden S, Eckhardt S, Basser R, de Boer R, Rischin D, Green M . Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005; 16(8):1391-7. DOI: 10.1093/annonc/mdi247. View

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T . Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004; 10(2):784-93. DOI: 10.1158/1078-0432.ccr-1100-03. View

Thatcher N, Chang A, Parikh P, Pereira J, Ciuleanu T, von Pawel J . Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366(9496):1527-37. DOI: 10.1016/S0140-6736(05)67625-8. View

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

10.

Pham D, Kris M, Riely G, Sarkaria I, McDonough T, Chuai S . Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24(11):1700-4. DOI: 10.1200/JCO.2005.04.3224. View

11.

Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H . A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2007; 1(9):1002-9. View

12.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

13.

Wu W, Onn A, Isobe T, Itasaka S, Langley R, Shitani T . Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007; 6(2):471-83. DOI: 10.1158/1535-7163.MCT-06-0416. View

14.

Hanrahan E, Ryan A, Mann H, Kennedy S, Langmuir P, Natale R . Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009; 15(10):3600-9. DOI: 10.1158/1078-0432.CCR-08-2568. View

15.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

16.

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello M, Aldinucci D . The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2007; 214(3):559-67. DOI: 10.1002/jcp.21260. View

17.

Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck T . Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2000; 276(5):3222-30. DOI: 10.1074/jbc.M002016200. View

18.

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F . Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25(12):1545-52. DOI: 10.1200/JCO.2005.05.1474. View

19.

Heymach J, Paz-Ares L, De Braud F, Sebastian M, Stewart D, Eberhardt W . Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26(33):5407-15. DOI: 10.1200/JCO.2008.17.3138. View

20.

Munoz-Chapuli R, Quesada A, Angel Medina M . Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci. 2004; 61(17):2224-43. PMC: 11138771. DOI: 10.1007/s00018-004-4070-7. View